About Sinovac
Sinovac is a company based in Haidian (China) founded in 2001 was acquired by SAIF Partners in June 2017. Sinovac operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Haidian, China
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website sinovac.com/en-us
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by SAIF Partners (Jun 2017)
- Latest Funding Round$515M (USD), Post-IPO
Dec 2020
- InvestorsSino Biopharmaceutical
& 7 more
- Acquired bySAIF Partners
(Jun 2017)
Apps and channels of Sinovac
its YouTube channel SinovacBiotech has 136 subscribers and 30 videos.
Videos from Sinovac
The most watched videos on Sinovac's YouTube channel, SinovacBiotech (136 subscribers). Click a video to play it here.
More on SinovacBiotech.
Funding Insights of Sinovac
- Total Rounds 7
- Last Round Post-IPO — $515M
- First Round $4.75M
(Feb 2004)
- Investors Count 4
All 7 funding rounds of Sinovac with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $515M | Post-IPO | – | – | |
| May 2020 | $15M | Post-IPO | – | – | |
| Jul 2018 | $86.7M | Post-IPO | – | – | |
| Apr 2014 | $9.71M | Grant | – | – | – |
| Feb 2008 | $9.75M | Post-IPO | – | – | – |
| Dec 2005 | $867,000 | Grant | – | – | |
| Feb 2004 | $4.75M | Post-IPO | – | – | – |
6 investors in total: 6 institutional.
Investors in Sinovac
Sinovac has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Sino Biopharmaceutical, Advantech Capital and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | advantechcapital.com | - | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
- | – | cbridgecap.com | - | |
Growth capital is provided to companies in China by SAIF Partners. | – | sbaif.com | Hong Kong, China | |
Generics for cardio-cerebral diseases and hepatitis are developed and manufactured. | 2000 | sinobiopharm.com | Hong Kong, China | |
- | – | most.gov.cn | - |
Investor details for Sinovac
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sinovac
5 dated milestones of Sinovac across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Sinovac is founded.
- Funding First funding round of $4.8M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by SAIF Partners.
- Funding Latest funding round, Post-IPO, of $515.0M.
Competitors of Sinovac
Sinovac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Sinovac
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sinovac
The website of Sinovac (sinovac.com) receives about 17K visits a month and ranks #1,529,920 among all websites worldwide, #2,026 in Biotechnology and Pharmaceuticals.
- Monthly visits17K
▲ 6.2% vs previous month
- Unique visitors6.9K
per month
- Global rank#1,529,920
among all websites
- Category rank#2,026
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit12 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Sinovac. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sanofi.cn | sanofi.cn | 100% | – | #2,165,674 | – |
phirda.com | phirda.com | 100% | – | #762,386 | – |
xiahepublishing.com | xiahepublishing.com | 81% | – | #582,285 | – |
upmc-cbn.org | upmc-cbn.org | 81% | – | – | – |
ajnr.org | ajnr.org | 61% | – | #188,555 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Sinovac
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Sinovac
Complete news archive for Sinovac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sinovac
10 companies that operate in the same segment as Sinovac (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sinovac
Sinovac was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Sinovac is headquartered in Haidian, China. It is registered at Haidian, Beijing, China.
Sinovac was established in 2001 in Haidian, China, within the biotechnology sector focused on vaccine development. Vaccines have been produced for hepatitis A and B, seasonal influenza, H5N1 avian flu, H1N1 swine flu, mumps, and canine rabies. The Panflu.1 H1N1 vaccine was manufactured for the Chinese Central Government. Ongoing efforts include pipeline vaccines for enterovirus 71, pneumococcal conjugate and polysaccharides, and rubella, addressing key public health needs.
Sinovac's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Sinovac has 6 investors. Key investors include Sino Biopharmaceutical, Advantech Capital, Vivo Capital, Ministry of Science and Technology of the People's Republic of China, and CBC Group.
Yes. Sinovac was acquired by SAIF Partners in June 2017.